Amount of DNA in plasma and cancer risk: A prospective study

被引:81
作者
Gormally, E
Hainaut, P
Caboux, E
Airoldi, L
Autrup, H
Malaveille, C
Dunning, A
Garte, S
Matullo, G
Overvad, K
Tjonneland, A
Clavel-Chapelon, F
Boffetta, P
Boeing, H
Trichopoulou, A
Palli, D
Krogh, V
Tumino, R
Panico, S
Bueno-De-Mesquita, HB
Peeters, PH
Lund, E
Gonzalez, CA
Martinez, C
Dorronsoro, M
Barricarte, A
Tormo, MJ
Quiros, JR
Berglund, G
Hallmans, G
Day, NE
Key, TJ
Veglia, F
Peluso, M
Norat, T
Saracci, R
Kaaks, R
Riboli, E
Vineis, P
机构
[1] Univ Turin, Canc Epidemiol Unit, Turin, Italy
[2] CPO Piemonte, Turin, Italy
[3] Int Agcy Res Canc, F-69372 Lyon, France
[4] Ist Mario Negri, Milan, Italy
[5] Dept Occupat & Environm Med, Aarhus, Denmark
[6] Univ Cambridge, Dept Oncol, Cambridge, England
[7] Genet Res Inst, Milan, Italy
[8] Inst Sci Interchange Fdn, Turin, Italy
[9] Aalborg Hosp, Dept Clin Epidemiol, Aarhus, Denmark
[10] Aarhus Univ Hosp, DK-8000 Aarhus, Denmark
[11] Univ Aarhus, Dept Epidemiol & Social Med, Aarhus, Denmark
[12] Danish Canc Soc, Inst Canc Epidemiol, Copenhagen, Denmark
[13] Inst Gustave Roussy, INSERM, U521, F-94805 Villejuif, France
[14] Deutsch Krebsforschungszentrum, Div Clin Epidemiol, D-6900 Heidelberg, Germany
[15] German Inst Human Nutr, Potsdam, Rehbucke, Germany
[16] Univ Athens, Sch Med, Dept Hyg & Epidemiol, GR-11527 Athens, Greece
[17] Sci Inst Tuscany, Ctr Studio & Prevenz Oncol, Mol & Nutr Epidemiol Unit, Florence, Italy
[18] Natl Canc Inst, Dept Epidemiol, I-20133 Milan, Italy
[19] Azienda Osped Civile MP Arezzo, Ragusa Canc Registry, Ragusa, Italy
[20] Univ Naples Federico II, Dept Clin & Expt Med, Naples, Italy
[21] Natl Inst Publ Hlth & Environm, Ctr Nutr & Hlth, NL-3720 BA Bilthoven, Netherlands
[22] Univ Utrecht, Med Ctr, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands
[23] Univ Tromso, Inst Community Med, Tromso, Norway
[24] Catalan Inst Oncol, Dept Epidemiol, Barcelona, Spain
[25] Andalusian Sch Publ Hlth, Granada, Spain
[26] Dept Publ Hlth Guipuzkoa, San Sebastian, Spain
[27] Inst Publ Hlth, Navarra, Spain
[28] Consejeria Sanidad & Consumo, Murcia, Spain
[29] Consejeria Salud & Serv Sanitarios Asturias, Direccion Gen Salud Publ, Oviedo, Spain
[30] Lund Univ, Malni Diet & Canc Study, Malmo, Sweden
[31] Umea Univ, Dept Nutr Res, Umea, Sweden
[32] MRC, Dunn Human Nutr Unit, Cambridge, England
[33] Univ Oxford, Canc Res UK Epidemiol Unit, Oxford, England
[34] Ctr Studio & Prevenz Oncol, Mol Biol Lab, I-50131 Florence, Italy
关键词
plasmatic DNA; cancer; prospective studies; molecular repidemiology;
D O I
10.1002/ijc.20327
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Levels of plasma DNA concentrations in cancer patients have been shown to be higher than the plasma DNA concentrations found in healthy subjects. The value of plasma DNA levels for development of neoplastic or pulmonary disease was evaluated in a large prospective study. Plasma samples (n = 1, 184) were analyzed from 776 controls, 359 cases of cancer (lung, bladder, oral cavity, pharynx, larynx, leukemia) and 49 deaths from chronic obstructive pulmonary disease (COPD), including never smokers and ex-smokers, from 9 countries across Europe. The amount of plasma DNA was variable across the European Prospective Investigation into Cancer and Nutrition (EPIC) centers. High DNA concentrations in some centers might be due to the type of population recruited and/or the treatment of the samples. An elevated and statistically significant odds ratio (OR) was found for COPID deaths (OR = 2.53; 95% CI = 1.06-6.02), while nonsignificant increased ORs were present for oral cancers, cancers of the pharynx and larynx and leukemia. When the analyses were stratified by time since recruitment (below or above 36 months), the increased ORs were limited to the more recent period of recruitment, i.e., a time elapsed between blood drawing and disease onset lower than 36 months. This was particularly true for COPID deaths (OR = 12.7; 95% CI = 1.57-103) and leukemia (OR = 2.37; 95% Cl = 1.20-4.67). (C) 2004 Wiley-Liss, Inc.
引用
收藏
页码:746 / 749
页数:4
相关论文
共 11 条
[1]  
Anker P, 2000, MEDICINA-BUENOS AIRE, V60, P699
[2]  
[Anonymous], INT J EPIDEMIOL S
[3]   Plasma DNA microsatellite panel as sensitive and tumor-specific marker in lung cancer patients [J].
Beau-Faller, M ;
Gaub, MP ;
Schneider, A ;
Ducrocq, X ;
Massard, G ;
Gasser, B ;
Chenard, MP ;
Kessler, R ;
Anker, P ;
Stroun, M ;
Weitzenblum, E ;
Pauli, G ;
Wihlm, JM ;
Quoix, E ;
Oudet, P .
INTERNATIONAL JOURNAL OF CANCER, 2003, 105 (03) :361-370
[4]  
Chang HW, 2002, JNCI-J NATL CANCER I, V94, P1697
[5]  
Gallagher A, 1999, INT J CANCER, V84, P442, DOI 10.1002/(SICI)1097-0215(19990820)84:4<442::AID-IJC20>3.3.CO
[6]  
2-A
[7]  
Holdenrieder S, 1999, ANTICANCER RES, V19, P2721
[8]   Molecular detection approaches for smoking associated tumors [J].
Hu, YC ;
Sidransky, D ;
Ahrendt, SA .
ONCOGENE, 2002, 21 (48) :7289-7297
[9]   Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from the Gambia [J].
Kirk, GD ;
Camus-Randon, AM ;
Mendy, M ;
Goedert, JJ ;
Merle, P ;
Trépo, C ;
Bréchot, C ;
Hainaut, P ;
Montesano, R .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (02) :148-153
[10]   Advances in cancer detection [J].
Sidransky, D .
SCIENTIFIC AMERICAN, 1996, 275 (03) :104-109